Liver Cancer
Vascular indices predict liver cancer responsiveness to thalidomide
Published in Hepatitis Weekly, June 13th, 2005
Researchers in Taiwan conducted a study "to prospectively evaluate the feasibility of using power Doppler ultrasonography (US) and measurement of circulating angiogenic factors to assess the antiangiogenic effect of thalidomide in hepatocellular carcinoma. The Ethics Committee of the National Taiwan University Hospital approved the study, and all patients gave prior written informed consent."
"Evaluation of response to thalidomide treatment was based on findings at computed tomography (CT) and change in serum alpha-fetoprotein level. Tumor vascularity index was evaluated with power...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
Source: Hepatitis Weekly (2005-06-13)
More Articles from Hepatitis Weekly
- Drug Research
Mizoribine and interferon unite to fight hepatitis C virus infection - Hepatitis C Therapy
Pegylated interferon enhances chronic hepatitis C triple therapy - Immunology
Complete steroid avoidance after liver transplantation yields adequate results - Stem Cell Research
Embryonic stem cells extend survival in rats with experimental liver failure - Transplant Medicine
Donor livers from octogenarians thrive after transplantation - Addiction Medicine
Mixed hepatitis C genotypes in injection drug users cut antiviral efficacy - More from this issue of Hepatitis Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
